Mirum Pharmaceuticals, Inc. MIRM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$790.16M-13,690% | -$5.73M-297% | $2.91M+150% | -$5.86M+60.1% | -$14.68M+38.3% | ||
| $6.87M+13.2% | $6.07M+0.2% | $6.06M+0.1% | $6.06M+0.1% | $6.05M-0.1% | ||
| $36.2M+90.3% | $19.03M+5.0% | $18.13M-1.8% | $18.47M+16.9% | $15.8M+19.3% | ||
| $454K+4.1% | $436K-1.6% | $443K+3.7% | $427K-1.4% | $433K+4.1% | ||
| $12.89M-32.2% | $19.01M+504% | $3.15M-65.3% | $9.07M-46.1% | $16.83M+54.9% | ||
| $1.92M-15.9% | $2.28M+96.9% | $1.16M-50.4% | $2.34M-12.6% | $2.67M+1,149% | ||
| $6.63M— | —— | $4.63M+13.4% | $4.09M+34.9% | $3.03M— | ||
| $278K-27.2% | $382K+10.7% | $345K+8.5% | $318K-10.7% | $356K-3.8% | ||
| -$583K-13.6% | -$513K+11.6% | -$580K-46.8% | -$395K+3.2% | -$408K-90.7% | ||
| -$228.76M-3,871% | $6.07M-84.7% | $39.68M+230% | $12.04M+714% | -$1.96M— | ||
| $664K+10.7% | $600K+221% | $187K+48.4% | $126K+207% | $41K+105% | ||
| $34.8M+203% | $11.5M-44.9% | $20.86M-33.9% | $31.54M-5.9% | $33.53M+192% | ||
| $33.89M+159% | $13.11M-30.4% | $18.82M-24.9% | $25.06M+43.8% | $17.43M+43.6% | ||
| $10M— | $0— | $0— | $0— | $0— | ||
| -$11.57M— | $0+100% | -$2.23M+66.3% | -$6.6M+59.1% | -$16.13M— | ||
| $10.13M+133% | -$31.14M-293% | $16.1M+85.3% | $8.69M+36.6% | $6.36M— | ||
| $270.08M+2,901% | $9M-44.1% | $16.1M+85.3% | $8.69M+36.6% | $6.36M+19.1% | ||
| -$1.27M— | —— | $349K-84.3% | $2.23M+111% | $1.06M+177% | ||
| $28.48M+81.8% | $15.66M-70.9% | $53.9M+230% | $16.36M+253% | -$10.68M-2,192% | ||
| $220K+3,567% | $6K-98.8% | $504K-66.1% | $1.49M+817% | $162K-30.5% | ||
| $454K+4.1% | $436K-1.6% | $443K+3.7% | $427K-1.4% | $433K+4.1% | ||
| $998K— | —— | —— | —— | $0— | ||
| $415.27M— | —— | —— | —— | $0— | ||
| -$1.1M— | —— | $643K+5.1% | $612K-7.0% | $658K+342% | ||
| $57.24M+1,563% | $3.44M-85.9% | $24.35M+130% | $10.58M-9.9% | $11.74M+25.7% | ||
| $71.79M— | —— | —— | —— | $0— | ||
| -$583K-13.6% | -$513K+11.6% | -$580K-46.8% | -$395K+3.2% | -$408K-90.7% | ||
| $4.8M+193% | $1.64M-39.0% | $2.68M+115% | $1.25M+1,259% | $92K+4,500% | ||
| $6.63M— | —— | $4.63M+13.4% | $4.09M+34.9% | $3.03M— | ||
| $0— | —— | -$540K— | —— | -$2.35M-183% | ||
| $550K+20.4% | $457K+2.2% | $447K+2.5% | $436K+11.8% | $390K+5.7% | ||
| $278K-27.2% | $382K+10.7% | $345K+8.5% | $318K-10.7% | $356K-3.8% | ||
| $10M— | $0— | $0— | $0— | $0— | ||
| $33.89M+159% | $13.11M-30.4% | $18.82M-24.9% | $25.06M+43.8% | $17.43M+43.6% | ||
| $259.95M— | —— | —— | —— | $0— | ||
| $10.13M+12.6% | $9M-44.1% | $16.1M+85.3% | $8.69M+36.6% | $6.36M+19.1% | ||
| $0-100% | $7K-12.5% | $8K+167% | $3K-50.0% | $6K— | ||
| -$1.27M— | —— | $349K-84.3% | $2.23M+111% | $1.06M+177% | ||
| -$583K-13.6% | -$513K+11.6% | -$580K-46.8% | -$395K+3.2% | -$408K-90.7% | ||
| $810K+18.1% | $686K-9.4% | $757K+34.2% | $564K-3.3% | $583K+48.3% | ||
| $0— | —— | —— | —— | $649K— | ||
| $4.47M+480% | $771K— | $0-100% | $1.67M— | $0— | ||
| $173K+19.3% | $145K-39.8% | $241K+168% | $90K-57.5% | $212K-0.5% | ||
| $9.56M— | —— | —— | —— | $0— | ||
| $220K+3,567% | $6K-98.8% | $504K-66.1% | $1.49M+817% | $162K-30.5% | ||
| -$229.43M-4,297% | $5.47M-86.2% | $39.49M+231% | $11.91M+695% | -$2M— | ||
| -$229.43M-4,297% | $5.47M-86.2% | $39.49M+231% | $11.91M+695% | -$2M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Mirum Pharmaceuticals, Inc. generate?
- Mirum Pharmaceuticals, Inc. (MIRM) generated -$171.0M in operating cash flow over the trailing twelve months.
- What is Mirum Pharmaceuticals, Inc.'s free cash flow?
- After $1.6M of capital expenditures, Mirum Pharmaceuticals, Inc.'s free cash flow was -$172.6M over the trailing twelve months, down 45270.7% year over year.
- Where does Mirum Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
